XTX Topco’s Celldex Therapeutics CLDX Stock Holding History

XTX Topco’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.8M	Buy	75,135 +63,061	+522%	+$2.04M	0.04%	794
2026 Q1	$383K	Sell	12,074 -39,449	-77%	-$1.08M	0.01%	2271
2025 Q4	$1.4M	Buy	51,523 +43,629	+553%	+$1.15M	0.04%	788
2025 Q3	$204K	Sell	7,894 -10,397	-57%	-$241K	0.01%	1833
2025 Q2	$372K	Buy	+18,291	New	+$356K	0.02%	1301
2025 Q1	–	Sell	-11,256	Closed	-$284K	–	2493
2024 Q4	$284K	Sell	11,256 -34,661	-75%	-$942K	0.02%	1270
2024 Q3	$1.56M	Buy	+45,917	New	+$1.75M	0.11%	224
2024 Q2	–	Sell	-5,534	Closed	-$232K	–	1941
2024 Q1	$232K	Buy	+5,534	New	+$227K	0.03%	1058
2023 Q4	–	Sell	-11,159	Closed	-$307K	–	1663
2023 Q3	$307K	Buy	+11,159	New	+$350K	0.05%	712

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco's CLDX Position: Q2 2026 in Review

XTX Topco increased its Celldex Therapeutics (CLDX) stake by 522% in Q2 2026, buying an estimated $2.04M and bringing the position to 75,135 shares worth $2.8M. The position accounts for 0.04% of the portfolio, ranked #794.

XTX Topco first reported a position in CLDX in Q3 2023 and has held it in 9 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

XTX Topco held 75,135 shares of Celldex Therapeutics worth $2.8M as of Q2 2026.
XTX Topco bought 63,061 Celldex Therapeutics shares in Q2 2026, an estimated $2.04M.
Celldex Therapeutics made up 0.04% of XTX Topco's portfolio in Q2 2026, its #794 holding.
XTX Topco first reported a position in Celldex Therapeutics in Q3 2023 and has held it in 9 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.